Gilead And Arcus Announced Anti-TIGIT Domvanalimab Continues To Demonstrate Consistent Improvement In Progression-Free Survival In Non-Small Cell Lung Cancer Study
Portfolio Pulse from Charles Gross
Gilead Sciences and Arcus Biosciences announced updated results from the interim analysis of the ARC-7 study, showing consistent improvement in progression-free survival in non-small cell lung cancer patients. The study evaluates the combinations of domvanalimab and zimberelimab, with results presented at the ASCO Plenary Series.
June 03, 2023 | 6:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences announced positive interim results from the ARC-7 study, which may boost investor confidence in the company's cancer treatment pipeline.
The positive interim results from the ARC-7 study indicate that Gilead's cancer treatment pipeline is progressing well. This may lead to increased investor confidence and a potential short-term increase in GILD's stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Arcus Biosciences announced positive interim results from the ARC-7 study, which may boost investor confidence in the company's cancer treatment pipeline.
The positive interim results from the ARC-7 study indicate that Arcus Biosciences' cancer treatment pipeline is progressing well. This may lead to increased investor confidence and a potential short-term increase in RCUS's stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50